The nation of Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) spanning five years over Washington's demand for confidential biological samples.
This move was revealed after a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government representative later stated that the United States was requesting biological samples for scientific study and commercial purposes while was unwilling to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued negotiations to find a deal agreeable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Background
This rejection comes after a similar case in Kenya, where a court halted a similar deal with the US following concerns were raised about the security of Kenyans' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral deals to enhance openness and accountability.
Based on reports, 16 African countries have so far signed similar agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our country would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our population if a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending frameworks already established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This framework is intended to guarantee that when a country provides its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent collaboration could be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body said it understood the official position, but suggested that negotiations must proceed since a large portion of the nation's Aids initiatives depended on external financing.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," the group commented.
The halted deal emphasises the continuing tensions between accepting vital international aid and protecting local interests in an increasingly data-driven world.